A Phase 1 interventional study of Ibuprofen and Diclofenac in Pain, sponsored by Futura Medical Developments Ltd.. Completed at 1 site in United Kingdom. Open to male participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-01-27.
Sponsored by Futura Medical Developments Ltd. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 86 studies testing ibuprofen in Pain — 6 open to participants now, 6 under way, none of them phase 3. Ibuprofen · Pain.
Among the 86 studies testing ibuprofen in Pain, this one is the 57th largest by enrollment, is one of 7 that started in 2015, is one of 9 in phase 1, and was the 49th registered.
10,069 studies on the registry are indexed under Pain; 1,651 are open to participants now.
Browse Pain studies →6 of the 86 studies testing ibuprofen in Pain are open now, in 4 countries. Recruiting first, the newest first:
Armed Forces Post Graduate Medical Institute (AFPGMI), Rawalpindi · Sites in Pakistan
Ages 18–60
October University for Modern Sciences and Arts · Sites in Egypt
Ages 6–12
Armed Forces Institute of Dentistry, Pakistan · Sites in Pakistan
Ages 18–50 · Healthy volunteers
Ankara City Hospital Bilkent · Sites in Turkey
Ages 18–80
Benaroya Research Institute · Sites in United States
Ages 18+ · Men only · Healthy volunteers
By country, each count listing its studies:
Ibuprofen: first FDA approval 1974 (MOTRIN), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 928 Pain studies recruiting now, 383 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 222 take healthy volunteers.
This study: 18 Years to 65 Years · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
86 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 10 · Phase 3 22 · Phase 4 30
First in 1998; this study’s year is marked. 7 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 60 is close to the median of 66 across 8,502 interventional studies indexed under Pain.
Median enrollment 100 across the 86 interventional studies. Of the 69 that completed or were terminated, 32 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
33 of 86 have an industry lead sponsor. The 10 most frequent:
Futura Medical Developments Ltd. is the lead sponsor of 6 studies on the registry; none are open to participants now.
Futura Medical Developments Ltd. has 1 study filed under Pain — fewer than ten, so there is no comparison to draw.
2 of the studies testing ibuprofen in Pain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07512297University of GaziantepPain Control During ESWL Using Non-Opioid Analgesics | 2027-01-01 |
| NCT07275710Armed Forces Post Graduate Medical Institute (AFPGMI), RawalpindiRole of Alprazolam in Management of Post Endodontic Pain After Single Visit Root Canal Treatment. To Compare Mean Pain Score Between Two Group of Participants Undergoing Post Operative Pain Management After Single Visit Root Canal Treatment: NSAIDs Alone and a Combination of NSAIDs and Alprazolam. | 2027-01-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 86 studies testing ibuprofen in Pain, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a randomised, double blind, cross over clinical study in healthy human volunteers (including pharmacokinetic [PK] sampling and laser Doppler assessment of local blood flow in a subset of up to 6 subjects per cohort of 20) to assess the efficacy and safety of three different topical analgesics (DCF100, TIB200 and SPR300) versus placebo and active control(s) in a model of UV-induced inflammatory pain.
This is a randomised, double blind, cross over clinical study in healthy human volunteers, including pharmacokinetic (PK) sampling and laser Doppler assessment of local blood flow in a subset of up to 6 subjects per cohort, to assess the efficacy and safety of three different topical analgesics (DCF100, TIB200 and SPR300) versus placebo and active control(s) in a model of UV-induced inflammatory pain. The study will consist of 3 cohorts of subjects (n=20 subjects per cohort). Subjects of each cohort will receive test and reference products (no reference product for Cohort 3) of one investigational medicinal product (IMP) and a placebo.
Test Products:
Cohort 1: Ibuprofen, TIB200 gel (10%, w/w) Cohort 2: Diclofenac, DCF100 gel (2% or 4%, w/w) Cohort 3: Methyl-salicylate and Menthol, SPR300 gel (15%:7%, w/w; ratio of Methylsalicylate to Menthol)
Reference Products:
Cohort 1: Ibuprofen, Nurofen Max Strength gel (10%, w/w), Ibuprofen, Nurofen, oral tablet (400 mg) Cohort 2: Voltaren Emulgel (2%), Voltarol oral tablet (50 mg)
Placebo:
All Cohorts:Test product matching vehicle gel.
Pharmacodynamic tests and PK blood draws will be performed at: pre-dose, 1, 2, 4, and 6 hours post dose for all treatment cohorts and treatment days (PK blood sampling in up to 6 subjects per cohort only).
Safety will be evaluated by the incidence of local and systemic treatment-emergent adverse events (TEAEs) reported after each treatment. Safety assessments will also include vital signs, 12-Lead Electrocardiograms (ECGs), laboratory tests and a physical examination at Screening and the Follow-up visit.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Subjects who, in the opinion of the PI, were considered unsuitable for any other reason.
-
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All Cohort 1 participants: TIB200 gel (10%, w/w ibuprofen)
Drug: Ibuprofen
All Cohort 1 participants: Nurofen Max Strength gel (10%, w/w ibuprofen)
Drug: Ibuprofen
All Cohort 1 participants: Nurofen oral tablets (2 x 400 mg ibuprofen)
Drug: Ibuprofen
All Cohort 1 Participants: TIB200 matching placebo gel
Drug: Placebo
All Cohort 2 Participants: DCF100 gel (2% w/w diclofenac)
Drug: Diclofenac
All Cohort 2 Participants: DCF100 gel (4% w/w diclofenac)
Drug: Diclofenac
All Cohort 2 Participants: Voltaren Emulgel (2% diclofenac)
Drug: Diclofenac
All Cohort 2 Participants: Voltarol oral tablet (50 mg - diclofenac)
Drug: Diclofenac
All Cohort 2 Participants: DCF100 matching placebo gel
Drug: Placebo
All Cohort 3 Participants: Methyl-salicylate / Menthol, SPR300 gel (15%:7%, w/w; ratio of Methylsalicylate / Menthol)
Drug: Methyl-salicylate / Menthol
All Cohort 3 Participants: SPR300 matching placebo gel
Drug: Placebo
Also known as: TIB200 gel 10%, Nurofen gel 10%, Nurofen tablets
Also known as: DCF100 gel 2%, DCF100 gel 4%, Voltaren gel 2%, Voltaren oral tablet
Drug page: Menthol
Also known as: SPR300 gel (15%/7%)
Also known as: TIB200 placebo gel, DCF100 placebo gel and SPR300 placebo gel
Heat Pain Tolerance Test (HPTT) Measured the Point at Which the Heat Became Painful - Degrees Centigrade -
To assess the pharmacodynamic effect by Heat Pain Tolerance Test (HPTT) which measured the point at which the heat became painful (degrees centigrade) of three topical analgesics, DCF100, TIB200, and SPR300 versus topical placebo and active topical reference products in a model of UV-induced inflammatory pain.
Time frame: 15 minutes before to 6 hours post administration
Intensity of the UVB-induced Erythema (Determined by Assessment of Skin Blood Flow by Laser Doppler Imaging [Flux Units])
Intensity of the Ultra Violet B radiation (UVB)-induced erythema (determined by assessment of skin blood flow by laser Doppler imaging \[flux units\], up to 8 subjects per cohort) - Change from baseline
Time frame: 15 minutes before to 6 hours post administration
Peak Plasma Concentration (Cmax)
Maximum observed plasma concentration (Cmax), time corresponding to occurrence of Cmax (tmax) (up to 6 subjects per cohort only) laser Doppler imaging \[flux units\], up to 6 subjects per cohort)
Time frame: 15 minutes before and 1, 2, 4 and 6 hours post administration
Area Under the Plasma Concentration Versus Time Curve
Area under the concentration vs. time curve from time zero to 6 hours (AUC0-6h) (up to 6 subjects per cohort only) laser Doppler imaging \[flux units\], up to 6 subjects per cohort)
Time frame: 15 minutes before and 1, 2, 4 and 6 hours post administration
Number of Recorded Abnormal Clinical Assessments
Laboratory assessments - standard clinical trial assessments for clinical chemistry and haematology Listing of individual laboratory measurements by subjects and evaluation of each laboratory parameter
Time frame: Estimated study duration for each subject will be approximately 6 weeks
Physical Exams to Ensure Safety and Well Being of the Subjects
Physical examinations - including assessments of the application site. examination.
Time frame: Estimated study duration for each subject will be approximately 6 weeks
Adverse Events (AEs)
Local and systemic Adverse Events (AEs).
Time frame: Estimated study duration for each subject will be approximately 6 weeks
To Determine Vital Signs and Electrocardiograms (ECGs) That Were Abnormal to Ensure Safety and Well Being of the Subjects
To determine Vital Signs and Electrocardiograms (ECGs) that were abnormal to ensure safety and well being of the subjects
Time frame: Estimated study duration for each subject will be approximately 6 weeks
| Milestone | Cohort 1 (Dosed on Days 1, 2 and 3) | Cohort 2 (Dosed on Days 1,2,3 and 4) | Cohort 3 (Dosed on Days 1 and 2) |
|---|---|---|---|
| Started | 20 | 20 | 20 |
| Completed | 20 | 20 | 20 |
| Not completed | 0 | 0 | 0 |
To assess the pharmacodynamic effect by Heat Pain Tolerance Test (HPTT) which measured the point at which the heat became painful (degrees centigrade) of three topical analgesics, DCF100, TIB200, and SPR300 versus topical placebo and active topical reference products in a model of UV-induced inflammatory pain.
| Degrees Centigrade | Cohort 1: TIB200 Gel 10% | Cohort 1: Nurofen Gel 10% | Cohort 1: Nurofen Tablets | Cohort 1: TIB200 Placebo Gel | Cohort 2: DCF100 Gel 2% | Cohort 2: DCF100 Gel 4% | Cohort 2: Voltaren Gel 2% | Cohort 2: Voltarol Oral Tablet | Cohort 2: DCF100 Placebo Gel | Cohort 3: SPR300 Gel (15%:7%) | Cohort 3: SPR300 Placebo Gel |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Heat Pain Tolerance Test (HPTT) Measured the Point at Which the Heat Became Painful - Degrees Centigrade - | 0.3635 ± 1.0277 | 0.7358 ± 1.0277 | 0.0887 ± 0.9024 | -0.1983 ± 0.4616 | 0.6679 ± 1.0657 | 0.8722 ± 1.0430 | 0.7978 ± 0.9780 | 0.6835 ± 0.7344 | 0.1688 ± 0.7231 | 0.3934 ± 1.2384 | -0.0123 ± 1.0103 |
Intensity of the Ultra Violet B radiation (UVB)-induced erythema (determined by assessment of skin blood flow by laser Doppler imaging \[flux units\], up to 8 subjects per cohort) - Change from baseline
| Laser doppler imaging (Flux Units) | Cohort 1: TIB200 Gel 10% | Cohort 1: Nurofen Gel 10% | Cohort 1: Nurofen Tablets | Cohort 1: TIB200 Placebo Gel | Cohort 2: DCF100 Gel 2% | Cohort 2: DCF100 Gel 4% | Cohort 2: Voltaren Gel 2% | Cohort 2: Voltarol Oral Tablet | Cohort 2: DCF100 Placebo Gel | Cohort 3: SPR300 Gel (15%:7%) | Cohort 3: SPR300 Placebo Gel |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Intensity of the UVB-induced Erythema (Determined by Assessment of Skin Blood Flow by Laser Doppler Imaging [Flux Units]) | -313.3879 ± 105.7042 | -171.5589 ± 96.6485 | -262.0693 ± 88.5449 | -95.3974 ± 81.4103 | -228.3016 ± 183.2260 | -278.1918 ± 103.7333 | -198.1408 ± 133.2886 | -198.1408 ± 211.2754 | -45.376 ± 104.4476 | 12.2265 ± 111.1065 | 67.3931 ± 91.092 |
Maximum observed plasma concentration (Cmax), time corresponding to occurrence of Cmax (tmax) (up to 6 subjects per cohort only) laser Doppler imaging \[flux units\], up to 6 subjects per cohort)
| ng/ml | Cohort 1: TIB200 Gel 10% | Cohort 1: Nurofen Gel 10% | Cohort 1: Nurofen Tablets | Cohort 2: DCF100 Gel 2% | Cohort 2: DCF100 Gel 4% | Cohort 2: Voltaren Gel 2% | Cohort 2: Voltarol Oral Tablet | Cohort 3: SPR300 Gel (15%:7%) | Cohort 3: SPR300 Placebo Gel |
|---|---|---|---|---|---|---|---|---|---|
| Peak Plasma Concentration (Cmax) | 11.5 ± 14 | 5.15 ± 8.1 | 29900 ± 5490 | 0 ± 0 | 0 ± 0 | 0 ± 0 | 772 ± 468 | 0 ± 0 | 0 ± 0 |
Area under the concentration vs. time curve from time zero to 6 hours (AUC0-6h) (up to 6 subjects per cohort only) laser Doppler imaging \[flux units\], up to 6 subjects per cohort)
| h*ng/ml | Cohort 1: TIB200 Gel 10% | Cohort 1: Nurofen Gel 10% | Cohort 1: Nurofen Tablets | Cohort 2: DCF100 Gel 2% | Cohort 2: DCF100 Gel 4% | Cohort 2: Voltaren Gel 2% | Cohort 2: Voltarol Oral Tablet | Cohort 3: SPR300 Gel (15%:7%) | Cohort 3: SPR300 Placebo Gel |
|---|---|---|---|---|---|---|---|---|---|
| Area Under the Plasma Concentration Versus Time Curve | 47.7 ± 64.3 | 19.9 ± 33.7 | 90000 ± 15400 | 0 ± 0 | 0 ± 0 | 0 ± 0 | 1030 ± 463 | 0 ± 0 | 0 ± 0 |
Laboratory assessments - standard clinical trial assessments for clinical chemistry and haematology Listing of individual laboratory measurements by subjects and evaluation of each laboratory parameter
| Assessments | Cohort 1: TIB200 Gel 10% | Cohort 1: Nurofen Gel 10% | Cohort 1: Nurofen Tablets | Cohort 1: TIB200 Placebo Gel | Cohort 2: DCF100 Gel 2% | Cohort 2: DCF100 Gel 4% | Cohort 2: Voltaren Gel 2% | Cohort 2: Voltarol Oral Tablet | Cohort 2: DCF100 Placebo Gel | Cohort 3: SPR300 Gel (15%:7%) | Cohort 3: SPR300 Placebo Gel |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Recorded Abnormal Clinical Assessments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Physical examinations - including assessments of the application site. examination.
| Abnormalities | Cohort 1: TIB200 Gel 10% | Cohort 1: Nurofen Gel 10% | Cohort 1: Nurofen Tablets | Cohort 1: TIB200 Placebo Gel | Cohort 2: DCF100 Gel 2% | Cohort 2: DCF100 Gel 4% | Cohort 2: Voltaren Gel 2% | Cohort 2: Voltarol Oral Tablet | Cohort 2: DCF100 Placebo Gel | Cohort 3: SPR300 Gel (15%:7%) | Cohort 3: SPR300 Placebo Gel |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Physical Exams to Ensure Safety and Well Being of the Subjects | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Local and systemic Adverse Events (AEs).
| Events | Cohort 1: TIB200 Gel 10% | Cohort 1: Nurofen Gel 10% | Cohort 1: Nurofen Tablets | Cohort 1: TIB200 Placebo Gel | Cohort 2: DCF100 Gel 2% | Cohort 2: DCF100 Gel 4% | Cohort 2: Voltaren Gel 2% | Cohort 2: Voltarol Oral Tablet | Cohort 2: DCF100 Placebo Gel | Cohort 3: SPR300 Gel (15%:7%) | Cohort 3: SPR300 Placebo Gel |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Adverse Events (AEs) | 5 | 5 | 1 | 1 | 1 | 1 | 0 | 2 | 0 | 3 | 1 |
To determine Vital Signs and Electrocardiograms (ECGs) that were abnormal to ensure safety and well being of the subjects
| Abnormal readings | Cohort 1: TIB200 Gel 10% | Cohort 1: Nurofen Gel 10% | Cohort 1: Nurofen Tablets | Cohort 1: TIB200 Placebo Gel | Cohort 2: DCF100 Gel 2% | Cohort 2: DCF100 Gel 4% | Cohort 2: Voltaren Gel 2% | Cohort 2: Voltarol Oral Tablet | Cohort 2: DCF100 Placebo Gel | Cohort 3: SPR300 Gel (15%:7%) | Cohort 3: SPR300 Placebo Gel |
|---|---|---|---|---|---|---|---|---|---|---|---|
| To Determine Vital Signs and Electrocardiograms (ECGs) That Were Abnormal to Ensure Safety and Well Being of the Subjects | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Collected over 3 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1: TIB200 Gel 10% | 0/20 (0%) | 0/20 (0%) | 5/20 (25%) |
| Cohort 1: Nurofen Gel 10% | 0/20 (0%) | 0/20 (0%) | 5/20 (25%) |
| Cohort 1: Nurofen Tablets | 0/20 (0%) | 0/20 (0%) | 1/20 (5%) |
| Cohort 1: TIB200 Placebo Gel | 0/20 (0%) | 0/20 (0%) | 1/20 (5%) |
| Cohort 2: DCF100 Gel 2% | 0/20 (0%) | 0/20 (0%) | 1/20 (5%) |
| Cohort 2: DCF100 Gel 4% | 0/20 (0%) | 0/20 (0%) | 1/20 (5%) |
| Cohort 2: Voltaren Gel 2% | 0/20 (0%) | 0/20 (0%) | 0/20 (0%) |
| Cohort 2: Voltarol Oral Tablet | 0/20 (0%) | 0/20 (0%) | 2/20 (10%) |
| Cohort 2: DCF100 Placebo Gel | 0/20 (0%) | 0/20 (0%) | 0/20 (0%) |
| Cohort 3: SPR300 Gel (15%:7%) | 0/20 (0%) | 0/20 (0%) | 3/20 (15%) |
| Cohort 3: SPR300 Placebo Gel | 0/20 (0%) | 0/20 (0%) | 1/20 (5%) |
| Event | Cohort 1: TIB200 Gel 10% | Cohort 1: Nurofen Gel 10% | Cohort 1: Nurofen Tablets | Cohort 1: TIB200 Placebo Gel | Cohort 2: DCF100 Gel 2% | Cohort 2: DCF100 Gel 4% | Cohort 2: Voltaren Gel 2% | Cohort 2: Voltarol Oral Tablet | Cohort 2: DCF100 Placebo Gel | Cohort 3: SPR300 Gel (15%:7%) | Cohort 3: SPR300 Placebo Gel |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ItchingSkin and subcutaneous tissue disorders | 1/20 | 4/20 | 0/20 | 0/20 | 1/20 | 0/20 | 0/20 | 0/20 | 0/20 | 0/20 | 0/20 |
| Pain BurningGeneral disorders | 1/20 | 0/20 | 0/20 | 1/20 | 0/20 | 0/20 | 0/20 | 0/20 | 0/20 | 2/20 | 0/20 |
| Back painMusculoskeletal and connective tissue disorders | 0/20 | 1/20 | 0/20 | 0/20 | 0/20 | 0/20 | 0/20 | 0/20 | 0/20 | 0/20 | 0/20 |
| toothacheGastrointestinal disorders | 0/20 | 0/20 | 1/20 | 0/20 | 0/20 | 0/20 | 0/20 | 0/20 | 0/20 | 0/20 | 0/20 |
| headacheGastrointestinal disorders | 1/20 | 0/20 | 0/20 | 0/20 | 0/20 | 0/20 | 0/20 | 0/20 | 0/20 | 0/20 | 0/20 |
| Hot FlushVascular disorders | 1/20 | 0/20 | 0/20 | 0/20 | 0/20 | 0/20 | 0/20 | 0/20 | 0/20 | 0/20 | 0/20 |
| NauseaGastrointestinal disorders | 1/20 | 0/20 | 0/20 | 0/20 | 0/20 | 0/20 | 0/20 | 0/20 | 0/20 | 0/20 | 0/20 |
| Frequency of Micturation IncreasedRenal and urinary disorders | 0/20 | 0/20 | 0/20 | 0/20 | 0/20 | 0/20 | 0/20 | 1/20 | 0/20 | 0/20 | 0/20 |
| Soft StoolsGastrointestinal disorders | 0/20 | 0/20 | 0/20 | 0/20 | 0/20 | 0/20 | 0/20 | 1/20 | 0/20 | 0/20 | 0/20 |
| Commom ColdInfections and infestations | 0/20 | 0/20 | 0/20 | 0/20 | 0/20 | 1/20 | 0/20 | 0/20 | 0/20 | 0/20 | 0/20 |
| Age, Categorical(Participants) | Cohort 1 | Cohort 2: | Cohort 3 | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 20 | 20 | 20 | 60 |
| >=65 years | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Cohort 1 | Cohort 2: | Cohort 3 | Total |
|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 |
| Male | 20 | 20 | 20 | 60 |
| Region of Enrollment(participants) | Cohort 1 | Cohort 2: | Cohort 3 | Total |
|---|---|---|---|---|
| United Kingdom | 20 | 20 | 20 | 20 |
Plan to share: No
No publications or documents are linked to this record.
The record gives a start of Mar 2015, a primary completion of May 2015 and a completion of May 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2020, 5 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ibuprofen · Diclofenac
Futura Medical Developments Ltd.